Loading
A phase 2 trial of YL202 should be intravenously infused in advanced solid tumours, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC is a phase 2 interventional study registered as NCT06439771 by MediLink Therapeutics (Suzhou) Co., Ltd., with 180 participants planned, started 2024-04-23 and due to reach its primary completion in 2026-07-30. Interventions recorded: YL202 should be intravenously infused.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares YL202, MediLink Therapeutics and the tag pipeline.
Shares MediLink Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares MediLink Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares MediLink Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares MediLink Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares HER2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares HER2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares HER2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/